KALY - Kali-Extracts Introduces Third Option To Compete With Two $50 Million Acquisition Offers
November 20 2019 - 9:35AM
InvestorsHub NewsWire
KALY - Kali-Extracts Introduces
Third Option To Compete With Two $50 Million Acquisition
Offers
Dallas, TX -- November 20, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced introducing a third option to
compete with the two acquisition offers currently being entertained
by KALY management. KALY has recently announced receiving two
inquiries into the acquisition of the company’s cannabis
biopharmaceutical technology valuing the technology at $50
million. KALY management is entertaining the inquiries but
indicates that the $50 million valuation is too low. KALY has
a U.S. Patented Cannabis Extraction Process and is developing
treatments for various medical conditions (see below).
Doctors working with KALY on the treatment developments have
compared KALY’s technology to GW Pharmaceuticals’ (GWPH)
and indicated the KALY solutions could be superior to GW
Pharma’s. KALY management today announced that in addition to
entertaining the two acquisition opportunities that could infuse
financing that accelerates its cannabis extract biopharmaceutical
technology developments, that the company is introducing a third
option that would not involve a sale of KALY’s biopharmaceutical
technology asset, but would otherwise restructure the asset within
KALY’s current corporate structure to facilitate a major infusion
of investment capital. KALY management plans to finalize the third
option plans within the next two weeks and make them
public.
KALY’s cannabis biopharmaceutical
technology intellectual property portfolio contains a deep pipeline
of cannabinoid product candidates including four distinct compounds
listed here:
Chronic Obstructive Pulmonary Disease
(COPD) - The market for
COPD treatment is anticipated to reach $14 billion by
2025;
Type
2 Diabetes - The market
for Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain Management - The overall pain management treatment market is
anticipated to reach $83 billion by 2024, and
Epilepsy -
The market for epilepsy treatment is anticipated to reach $9
billion by 2022.
In
conjunction with the research already conducted and the next phase
of research now moving forward, KALY recently filed for a new
patent application specifically on its formulation for symptoms
associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition
to KALY’s ongoing efforts to develop prescription therapies, KALY
has initiated a program to certify its proprietary CBD extracts
derived from KALY’s U.S. Patented Extraction Process as an
Over-The-Counter (OTC) drug under the requirements prescribed by
the U.S. Food and Drug
Administration.
To stay abreast of the latest
developments and learn more about the company visit https://www.kali-extracts.com/.
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024